Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 4/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.31 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2915801 | 1.00 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| Hydrochloric Acid SCHEMBL15253811 | 0.97 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL1025430 | 0.97 | CYP3A4 (0.41) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL35092 | 0.97 | CYP3A4 (0.45) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL954340 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL7934432 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL556980 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL22749132 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL22749145 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 | |
| SCHEMBL31379074 | 0.94 | CYP3A4 (0.43) | CYP3A4TDP1ESR1ESR2KCNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111132981-B | Process for preparing pyrido [1,2-A ] pyrimidin-4-one derivatives | 豪夫迈·罗氏有限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-102617690-B | Vitamin d derivatives | CHUGAI PHARMACEUTICAL CO LTD | 2015-07-08 | — | — | CN | claimed |
| CN-122029142-A | Improved process for synthesizing all (E) -heptaisopentenol (C35-OH) | 辛纳吉亚生命科学私人有限公司 | 2026-05-12 | — | — | CN | disclosed |
| WO-2026047037-A1 | MICROBIOCIDAL QUINOLINE-AMIDE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2026-03-05 | — | — | WO | disclosed |
| US-20260015309-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | SYNERGIA LIFE SCIENCES PVT. LTD. (IN) | 2026-01-15 | — | — | US | disclosed |
| EP-4663641-A2 | PROCESS FOR THE PREPRATION OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| WO-2025233384-A1 | MICROBIOCIDAL PYRAZOLE COMPOUNDS | SYNGENTA CROP PROTECTION AG (CH) | 2025-11-13 | — | — | WO | disclosed |
| EP-3684766-B1 | PROCESS FOR THE PREPRATION OF 7-(4,7-DIAZASPIRO[2.5]OCTAN-7-YL)-2-(2,8-DIMETHYLIMIDAZO[1,2-B]PYRIDAZIN-6-YL)PYRIDO[1,2-A]PYRIMIDIN-4-ONE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-10-29 | — | — | EP | disclosed |
| EP-4615829-A1 | MICROBIOCIDAL PYRAZOLE DERIVATIVES | Syngenta Crop Protection AG (CH) | 2025-09-17 | — | — | EP | disclosed |
| EP-4554925-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | Synergia Life Sciences Pvt. Ltd (IN) | 2025-05-21 | — | — | EP | disclosed |
| WO-2025074315-A2 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF ALL (E)-HEPTA PRENOL (C35-OH) | SYNERGIA LIFE SCIENCES PVT. LTD. (IN) | 2025-04-10 | — | — | WO | disclosed |
| US-7186865-B2 | Reacting optically active secondary amine with alkylation agent in presence of a base, thereby converting the secondary amine into an optically active tertiary amine and subjecting the tertiary amine to hydrogenolysis, producing the N-monoalkyl derivative; intermediates for drugs, agriculture | CENTRAL GLASS COMPANY, LIMITED (JP) | 2007-03-06 | — | — | US | disclosed |
| US-6852662-B2 | Catalyst systems based on transition metal complexes for carbon monoxide copolymerization in an aqueous medium | BASF AKTIENGESELLSCHAFT (DE) | 2005-02-08 | — | — | US | disclosed |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2004-11-25 | — | — | US | disclosed |
| EP-0732336-B1 | Process for the preparation of arylalkyl phosphines, arylalkyl phosphine oxides or arylalkyl phosphine sulfides | CYTEC CANADA INC (CA) | 2000-12-20 | — | — | EP | disclosed |
| WO-2000049088-A1 | POLYMER BLENDS MADE OF FUNCTIONALISED CARBON MONOXIDE COPOLYMERS AND POLYAMIDES | BASF AKTIENGESELLSCHAFT (DE) | 2000-08-24 | — | — | WO | disclosed |
| US-5723621-A | Process for processing biaryl compound | CHISSO CORPORATION (JP) | 1998-03-03 | — | — | US | disclosed |
| EP-0732336-A1 | Process for the preparation of arylalkyl phosphines, arylalkyl phosphine oxides or arylalkyl phosphine sulfides | Cytec Canada Inc. (CA) | 1996-09-18 | — | — | EP | disclosed |
| US-5550295-A | Preparation of arylalkyl phosphines, phosphine oxides or phosphine sulfides | CYTEC TECHNOLOGY CORP. (US) | 1996-08-27 | — | — | US | disclosed |
| US-5510518-A | Process for the hydrosulfination of olefins | HOECHST AKTIENGESELLSCHAFT (DE) | 1996-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015309-A1 | PROCESS FOR THE SYNTHESIS OF VITAMIN K2 | PROC, TPRKB, KCNK9 | CYP3A4 626/4885TDP1 4788/4885ESR1 1590/4885 |
| US-20040235961-A1 | Optically active 1-(fluoro-, trifluoromethyl-or trifluoromethoxy-substituted phenyl) alkylamine n-monoalkyl derivatives and process for producing same | NAT1, PNMT, AFF1 | CYP3A4 145/4885TDP1 1702/4885ESR1 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.